Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SJ-600
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : ReiThera
Deal Size : Undisclosed
Deal Type : Partnership
ReiThera Partners with SillaJen to Develop & Produce the SJ-600 Series for Clinical Trials
Details : Through the partnership, ReiThera will leverage its expertise to conduct advanced development & production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 24, 2025
Lead Product(s) : SJ-600
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : ReiThera
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : OSR Holdings
Deal Size : Undisclosed
Deal Type : Collaboration
OSR Holdings and SillaJen Sign MOU to Develop Innovative Therapeutics in US Market
Details : The collaboration will explore various ways to create synergies between current platform technologies and new drug candidates, including BAL0891, a mitotic checkpoint inhibitor targeting solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : OSR Holdings
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Details : Pexa-Vec (pexastimogene devacirepvec) is a vaccinia virus based oncolytic immunotherapy is being evaluated in combination with cemiplimab for metastatic or unresectable renal cell carcinoma.
Product Name : Pexa-Vec
Product Type : Microorganism
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Details : BAL0891 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Basilea Pharmaceutica
Deal Size : $14.0 million
Deal Type : Agreement
Details : BAL0891 is a potential first-in-class mitotic checkpoint inhibitor that drives aberrant tumor cell division leading to tumor cell death. A first poster showed in-vitro data on the activity of BAL0891 against its targets, threonine tyrosine kinase and pol...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
December 19, 2022
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Basilea Pharmaceutica
Deal Size : $14.0 million
Deal Type : Agreement
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Basilea Pharmaceutica
Deal Size : $334.0 million
Deal Type : Licensing Agreement
Details : The agreement for a novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, demonstrates the commitment to enhance lives of patients suffering from advanced solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : BAL0891
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Basilea Pharmaceutica
Deal Size : $334.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Pexa Vec
Product Type : Microorganism
Upfront Cash : Inapplicable
September 26, 2017
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Pexa Vec
Product Type : Microorganism
Upfront Cash : Inapplicable
September 29, 2015
Lead Product(s) : Pexastimogene devacirepvec
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 10, 2012
Lead Product(s) : JX-594
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Transgene
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 15, 2011
Lead Product(s) : JX-594
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Transgene
Deal Size : Inapplicable
Deal Type : Inapplicable